Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care: Essential Guidance on Translating Scientific Advances With Novel HER2-Targeted Therapies and Other Agents Into Current Clinical Practice


Manage episode 270839263 series 103583
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

65 episodes